JPWO2021119832A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021119832A5 JPWO2021119832A5 JP2022538373A JP2022538373A JPWO2021119832A5 JP WO2021119832 A5 JPWO2021119832 A5 JP WO2021119832A5 JP 2022538373 A JP2022538373 A JP 2022538373A JP 2022538373 A JP2022538373 A JP 2022538373A JP WO2021119832 A5 JPWO2021119832 A5 JP WO2021119832A5
- Authority
- JP
- Japan
- Prior art keywords
- mutations
- domain
- polypeptide
- protein complex
- numbering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000035772 mutation Effects 0.000 claims 61
- 229920001184 polypeptide Polymers 0.000 claims 34
- 108090000765 processed proteins & peptides Proteins 0.000 claims 34
- 102000004196 processed proteins & peptides Human genes 0.000 claims 34
- 102000004169 proteins and genes Human genes 0.000 claims 28
- 108090000623 proteins and genes Proteins 0.000 claims 28
- 238000006471 dimerization reaction Methods 0.000 claims 23
- 239000000427 antigen Substances 0.000 claims 18
- 102000036639 antigens Human genes 0.000 claims 18
- 108091007433 antigens Proteins 0.000 claims 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 210000004899 c-terminal region Anatomy 0.000 claims 5
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 3
- 230000002519 immonomodulatory effect Effects 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 210000002865 immune cell Anatomy 0.000 claims 2
- 239000001601 sodium adipate Substances 0.000 claims 2
- 241000251468 Actinopterygii Species 0.000 claims 1
- 102000019034 Chemokines Human genes 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 239000000833 heterodimer Substances 0.000 claims 1
- 230000008938 immune dysregulation Effects 0.000 claims 1
- 102000027596 immune receptors Human genes 0.000 claims 1
- 108091008915 immune receptors Proteins 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000001608 potassium adipate Substances 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Claims (25)
X-[(Aba)-(Lb)]m-(DD)-[(Lc)-(Abd)]n-Y
のアミノ酸配列をそれぞれ含む第1のポリペプチド及び第2のポリペプチドを含むタンパク質複合体、あるいはN末端からC末端への様式において式Ibのアミノ酸配列を含むポリペプチドであって、
mが、0、1又は1より大きい整数であり;
nが2又は2より大きい整数であり;
Aba、Abdが各々独立して、抗体の1つ又は複数の相補性決定領域(CDR)を含む抗原結合性ドメインを含み;
X又はYが独立して存在するか又は存在せず、アミノ酸配列を含み;
Lb、Lcが各々独立して1つ又は複数のリンカーを含み;
Lcが、切断可能なリンカーを含まず;且つ
DDが二量体化ドメインを含み、
タンパク質複合体の第1及び第2のポリペプチドは、同一である又は異なる、
タンパク質複合体又はポリペプチド。 Formula Ib in an N-terminal to C-terminal manner:
X-[(Ab a )-(L b )] m -(DD)-[(L c )-(Ab d )] n -Y
a protein complex comprising a first polypeptide and a second polypeptide each comprising an amino acid sequence of formula Ib, or a polypeptide comprising an amino acid sequence of formula Ib in an N-terminal to C-terminal manner ,
m is 0, 1, or an integer greater than 1;
n is 2 or an integer greater than 2;
Ab a , Ab d each independently comprises an antigen-binding domain comprising one or more complementarity determining regions (CDRs) of the antibody;
X or Y independently present or absent, comprising an amino acid sequence;
L b , L c each independently include one or more linkers;
L c does not contain a cleavable linker; and
DD contains a dimerization domain,
the first and second polypeptides of the protein complex are the same or different ;
Protein complex or polypeptide.
X-[(Aba)-(Lb)]m-(DD)-[(Lc)-(Abd)]n-Y
のアミノ酸配列をそれぞれ含む第1のポリペプチド及び第2のポリペプチドを含むタンパク質複合体、あるいはN末端からC末端への様式において式Icのアミノ酸配列を含むポリペプチドであって、
mが、0、1又は1より大きい整数であり;
nが、0、1又は1より大きい整数であり、但しm及びnが同時に0ではなく;
Aba、Abdが各々独立して、抗体の1つ又は複数の相補性決定領域(CDR)を含む抗原結合性ドメインを含み;
X又はYが独立して存在するか又は存在せず、アミノ酸配列を含み;
Lb、Lcが各々独立して1つ又は複数のリンカーを含み;
DDが、
EUナンバリングにしたがってD399、D/E356及び/若しくはK370に対応する位置における1つ若しくは複数の突然変異を含むCH3ドメイン;
又は
EUナンバリングにしたがってD399、E357及び/若しくはK439に対応する位置における1つ若しくは複数の突然変異を含むCH3ドメイン
を含む二量体化ドメインを含み、
タンパク質複合体の第1及び第2のポリペプチドは、同一である又は異なる、
タンパク質複合体又はポリペプチド。 Formula Ic in an N-terminal to C-terminal manner:
X-[(Ab a )-(L b )] m -(DD)-[(L c )-(Ab d )] n -Y
a protein complex comprising a first polypeptide and a second polypeptide, each comprising an amino acid sequence of formula Ic, or a polypeptide comprising an amino acid sequence of formula Ic in an N-terminal to C-terminal manner ,
m is 0, 1, or an integer greater than 1;
n is 0, 1, or an integer greater than 1, provided that m and n are not simultaneously 0;
Ab a , Ab d each independently comprises an antigen-binding domain comprising one or more complementarity determining regions (CDRs) of the antibody;
X or Y independently present or absent, comprising an amino acid sequence;
L b , L c each independently include one or more linkers;
DD is
a CH3 domain containing one or more mutations at positions corresponding to D399, D/E356 and/or K370 according to EU numbering;
or
comprising a dimerization domain comprising a CH3 domain comprising one or more mutations at positions corresponding to D399, E357 and/or K439 according to EU numbering;
the first and second polypeptides of the protein complex are the same or different ;
Protein complex or polypeptide.
a.突然変異D399N、E356Q、K370E;
b.突然変異D399N、E357Q、K439E;
c.突然変異D399Q、D/E356Q、K370E、Y349K及びS354K;
d.突然変異D399N、D/E356Q、K370E及びL351W;
e.突然変異D399N、D/E356Q、K370E及びS354M;
f.突然変異D399N、D/E356Q、K370E及びT350I;
g.突然変異D399N、D/E356Q、K370E及びT350V;
h.突然変異D399N、D/E356Q、K370E及びP352R;
i.突然変異D399N、D/E356Q、K370E及びP352E;
j.突然変異D399Q、D/E356Q及びK370E;
k.突然変異D399N、D/E356Q、K370E及びL351Y;
l.突然変異D399N、D/E356Q、K370E、及びL351H;
m.突然変異D399N、D/E356Q、K370E、及びR355K;
n.突然変異D399N、D/E356Q、K370E、及びQ355K;
o.突然変異D399N、D/E356Q、K370E及びS354K;
p.突然変異D399N、D/E356Q、K370E及びT350L;
q.突然変異D399N、D/E356Q、K370E及びT394N;
r.突然変異D399N、D/E356Q、K370E及びP352Y;
s.突然変異D399N、D/E356Q、K370E及びP352V;
t.突然変異D399N、D/E356Q、K370E及びP352T;
u.突然変異D399N、D/E356Q、K370E及びP352L;
v.突然変異D399N、D/E356Q、K370E及びP352G;
w.突然変異D399N、D/E356Q、K370E及びP352C;
x.突然変異D399N、D/E356Q、K370E及びL351T;
y.突然変異D399N、D/E356Q、K370E及びL351A;
z.突然変異D399Q、E357Q、K439E、Y349D及びS354D;
aa.突然変異D399N、E357Q、K439E及びL351R;
bb.突然変異D399N、E357Q、K439E及びL351Y;
cc.突然変異D399N、E357Q、K439E及びT350I;
dd.突然変異D399N、E357Q、K439E及びT350V;
ee.突然変異D399Q、K439E、E357Q;
ff.突然変異D399N、K439E、E357Q、S354K;
gg.突然変異D399N、K439E、E357Q、S354W;
hh.突然変異D399N、K439E、E357Q、Y349R;
ii.突然変異D399N、K439E、E357Q、T350L;
jj.突然変異D399N、K439E、E357Q、R355W;
kk.突然変異D399N、K439E、E357Q、Q355W;
ll.突然変異D399N、K439E、E357Q、P395I;
mm.突然変異D399N、K439E、E357Q、P395G;
nn.突然変異D399N、K439E、E357Q、P395E;
oo.突然変異D399N、K439E、E357Q、P352K;
pp.突然変異D399N、K439E、E357Q、P352D;あるいは
qq.突然変異D399N、K439E、E357Q、L351D
を含む、請求項3又は4に記載のタンパク質複合体又はポリペプチド。 The CH3 domain, according to EU numbering,
a. Mutations D399N , E 356Q, K370E;
b. Mutations D399N, E357Q, K439 E;
c. Mutations D399Q, D/E356Q, K370E, Y349K and S354K;
d. Mutations D399N, D/E356Q, K370E and L351W;
e. Mutations D399N, D/E356Q, K370E and S354M;
f. Mutations D399N, D/E356Q, K370E and T350I;
g. Mutations D399N, D/E356Q, K370E and T350V;
h. Mutations D399N, D/E356Q, K370E and P352R;
i. Mutations D399N, D/E356Q, K370E and P352E;
j. Mutations D399Q, D/E356Q and K370E;
k. Mutations D399N, D/E356Q, K370E and L351Y;
l. Mutations D399N, D/E356Q, K370E, and L351H;
m. Mutations D399N, D/E356Q, K370E, and R355K;
n. Mutations D399N, D/E356Q, K370E, and Q355K;
o. Mutations D399N, D/E356Q, K370E and S354K;
p. Mutations D399N, D/E356Q, K370E and T350L;
q. Mutations D399N, D/E356Q, K370E and T394N;
r. Mutations D399N, D/E356Q, K370E and P352Y;
s. mutations D399N, D/E356Q, K370E and P352V;
t. mutations D399N, D/E356Q, K370E and P352T;
u. Mutations D399N, D/E356Q, K370E and P352L;
v. Mutations D399N, D/E356Q, K370E and P352G;
w. Mutations D399N, D/E356Q, K370E and P352C;
x. Mutations D399N, D/E356Q, K370E and L351T;
y. Mutations D399N, D/E356Q, K370E and L351A;
z. Mutations D399Q, E357Q, K439E, Y349D and S354D;
aa. Mutations D399N, E357Q, K439E and L351R;
bb. Mutations D399N, E357Q, K439E and L351Y;
cc. mutations D399N, E357Q, K439E and T350I;
dd. Mutations D399N, E357Q, K439E and T350V;
ee. Mutations D399Q, K439E, E357Q;
ff. Mutations D399N, K439E, E357Q, S354K;
gg. Mutations D399N, K439E, E357Q, S354W;
hh. Mutations D399N, K439E, E357Q, Y349R;
ii. Mutations D399N, K439E, E357Q, T350L;
jj. Mutations D399N, K439E, E357Q, R355W;
kk. Mutations D399N, K439E, E357Q, Q355W;
ll. Mutations D399N, K439E, E357Q, P395I;
mm. Mutations D399N, K439E, E357Q, P395G;
nn. Mutations D399N, K439E, E357Q, P395E;
oo. Mutations D399N, K439E, E357Q, P352K;
pp. Mutation D399N, K439E, E357Q, P352D; or
qq. Mutation D399N, K439E, E357Q, L351 D
The protein complex or polypeptide according to claim 3 or 4 , comprising :
a.GSリンカーを含み、任意選択で配列番号7に示されるアミノ酸配列を含む柔軟性リンカー;
b.複数のPAリピートを含み、任意選択でPAPAPKA(配列番号8);APAPAPAPAPKA(配列番号9);APAPAPAPAPAPAPAPAPAPKA(配列番号10);又はこれらの組合せから選択される剛性リンカー;あるいは
c.配列番号15に示されるアミノ酸配列を含み、任意選択でAEAAAKEAAAKA(配列番号12);AEAAAKEAAAKEAAAKA(配列番号13);AEAAAKEAAAKEAAAKEAAAKEAAAKA(配列番号14);又はこれらの組合せから選択されるらせん状リンカー
である、請求項6に記載のタンパク質複合体又はポリペプチド。 The linker:
a. A flexible linker comprising a GS linker and optionally comprising the amino acid sequence set forth in SEQ ID NO: 7 ;
b. a rigid linker comprising multiple PA repeats and optionally selected from PAPAPKA (SEQ ID NO: 8); APAPAPAPAPKA (SEQ ID NO: 9); APAPAPAPAPAPAPAPAPAPKA (SEQ ID NO: 10); or a combination thereof; or
c. A helical linker comprising the amino acid sequence shown in SEQ ID NO: 15 and optionally selected from AEAAAKEAAAKA (SEQ ID NO: 12); AEAAAKEAAAKEAAAKA (SEQ ID NO: 13); AEAAAKEAAAKEAAAKEAAAAKEAAAKA (SEQ ID NO: 14); or a combination thereof.
7. The protein complex or polypeptide according to claim 6 .
X-(Aba1)-(Lb1)-(DD)-(Lc1)-(Abd1)-Y (式II);
X-(Aba1)-(Lb1)-(DD)-(Lc1)-(Abd1)-(Lc2)-(Abd2)-Y (式III);
X-(Aba1)-(Lb2)-(Aba2)-(Lb1)-(DD)-(Lc1)-(Abd1)-Y (式IV);
X-(Aba1)-(Lb2)-(Aba2)-(Lb1)-(DD)-(Lc1)-(Abd1)-(Lc2)-(Abd2)-Y (式V)
X-(Aba1)-(Lb2)-(Aba2)-(Lb1)-(DD)-(Lc1)-(Abd1)-(Lc2)-(Abd2)-(Lc3)-(Abd3)-Y (式VI);
X-(Aba1)-(Lb3)-(Aba2)-(Lb2)-(Aba3)-(Lb1)-(DD)-(Lc1)-(Abd1)-(Lc2)-(Abd2)-Y (式VII);
X-(Aba1)-(Lb3)-(Aba2)-(Lb2)-(Aba3)-(Lb1)-(DD)-(Lc1)-(Abd1)-(Lc2)-(Abd2)-(Lc3)-(Abd3)-Y (式VIII)
からなる群から選択される、請求項1~8のいずれか一項に記載のタンパク質複合体又はポリペプチド。 The polypeptide is :
X-(Ab a1 )-(L b1 )-(DD)-(L c1 )-(Ab d1 )-Y (Formula II);
X-(Ab a1 )-(L b1 )-(DD)-(L c1 )-(Ab d1 )-(L c2 )-(Ab d2 )-Y (Formula III);
X-(Ab a1 )-(L b2 )-(Ab a2 )-(L b1 )-(DD)-(L c1 )-(Ab d1 )-Y (formula IV);
X-(Ab a1 )-(L b2 )-(Ab a2 )-(L b1 )-(DD)-(L c1 )-(Ab d1 )-(L c2 )-(Ab d2 )-Y (Formula V )
X-(Ab a1 )-(L b2 )-(Ab a2 )-(L b1 )-(DD)-(L c1 )-(Ab d1 )-(L c2 )-(Ab d2 )-(L c3 ) -(Ab d3 )-Y (Formula VI);
X-(Ab a1 )-(L b3 )-(Ab a2 )-(L b2 )-(Ab a3 )-(L b1 )-(DD)-(L c1 )-(Ab d1 )-(L c2 ) -(Ab d2 )-Y (formula VII);
X-(Ab a1 )-(L b3 )-(Ab a2 )-(L b2 )-(Ab a3 )-(L b1 )-(DD)-(L c1 )-(Ab d1 )-(L c2 ) -(Ab d2 )-(L c3 )-(Ab d3 )-Y (Formula VIII)
The protein complex or polypeptide according to any one of claims 1 to 8 , selected from the group consisting of:
a.腫瘍により発現されるタンパク質に結合する少なくとも1つの抗原結合性ドメイン、免疫細胞に結合し且つそれを動員する少なくとも1つの抗原結合性ドメイン;
b.腫瘍により発現されるタンパク質に結合する少なくとも1つの抗原結合性ドメイン、免疫チェックポイントタンパク質に結合する少なくとも1つの抗原結合性ドメイン、及び免疫細胞に結合し且つそれを動員する少なくとも1つの抗原結合性ドメイン;あるいは
c.腫瘍抗原に結合する抗原結合性ドメイン、及び免疫調節因子に結合する抗原結合性ドメイン
を含む、請求項1~11のいずれか一項に記載のタンパク質複合体又はポリペプチド。 The polypeptide is
a. at least one antigen-binding domain that binds to a protein expressed by the tumor, at least one antigen-binding domain that binds to and recruits immune cells ;
b. at least one antigen-binding domain that binds to a protein expressed by the tumor, at least one antigen-binding domain that binds to an immune checkpoint protein, and at least one antigen-binding domain that binds to and recruits immune cells. sexual domain; or
c. Antigen-binding domain that binds to tumor antigens and antigen-binding domains that bind to immunomodulatory factors
The protein complex or polypeptide according to any one of claims 1 to 11 , comprising:
並びに
1つ又は複数の抗原結合性ドメイン、及びEUナンバリングにしたがってD399、E357及び/又はK439に対応する位置における1つ又は複数の突然変異を含むCH3ドメインを含む第2の二量体化ドメイン(DD2)を含む第2のポリペプチド
を含み、
前記第1及び第2のポリペプチドが二量体を形成し、任意選択で、
a.前記第1の二量体化ドメイン(DD 1 )が、EUナンバリングにしたがって突然変異D399Q、D/E356Q、K370E、Y349K及びS354Kを含むCH3ドメインを含み、且つ前記第2の二量体化ドメイン(DD 2 )が、EUナンバリングにしたがって突然変異D399Q、E357Q、K439E、Y349D及びS354Dを含むCH3ドメインを含む、
b.前記第1の二量体化ドメイン(DD 1 )が、EUナンバリングにしたがって突然変異D399N、D/E356Q、K370E及びL351Wを含むCH3ドメインを含み、且つ前記第2の二量体化ドメイン(DD 2 )が、EUナンバリングにしたがって突然変異D399N、E357Q、K439E及びL351Rを含むCH3ドメインを含む、
c.前記第1の二量体化ドメイン(DD 1 )が、EUナンバリングにしたがって突然変異D399N、D/E356Q、K370E及びS354Mを含むCH3ドメインを含み、且つ前記第2の二量体化ドメイン(DD 2 )が、EUナンバリングにしたがって突然変異D399N、E357Q、K439E及びL351Yを含むCH3ドメインを含む、
d.前記第1の二量体化ドメイン(DD 1 )が、EUナンバリングにしたがって突然変異D399N、D/E356Q、K370E及びT350Iを含むCH3ドメインを含み、且つ前記第2の二量体化ドメイン(DD 2 )が、EUナンバリングにしたがって突然変異D399N、E357Q、K439E及びT350Iを含むCH3ドメインを含む、
e.前記第1の二量体化ドメイン(DD 1 )が、EUナンバリングにしたがって突然変異D399N、D/E356Q、K370E及びT350Vを含むCH3ドメインを含み、且つ前記第2の二量体化ドメイン(DD 2 )が、EUナンバリングにしたがって突然変異D399N、E357Q、K439E及びT350Vを含むCH3ドメインを含む、
f.前記第1の二量体化ドメイン(DD 1 )が、EUナンバリングにしたがって突然変異D399N、D/E356Q、K370E及びP352Rを含むCH3ドメインを含み、且つ前記第2の二量体化ドメイン(DD 2 )が、EUナンバリングにしたがって突然変異D399N、E357Q、K439E及びL351Rを含むCH3ドメインを含む、あるいは
g.前記第1の二量体化ドメイン(DD 1 )が、EUナンバリングにしたがって突然変異D399N、D/E356Q、K370E及びP352Eを含むCH3ドメインを含み、且つ前記第2の二量体化ドメイン(DD 2 )が、EUナンバリングにしたがって突然変異D399N、E357Q、K439E及びL351Rを含むCH3ドメインを含む、
タンパク質複合体。 a first dimerization domain comprising one or more antigen binding domains and a CH3 domain comprising one or more mutations at positions corresponding to D399, D/E356 and/or K370 according to EU numbering a first polypeptide comprising (DD 1 );
and
a second dimerization domain (DD 2 ),
said first and second polypeptides form a dimer , and optionally,
a. said first dimerization domain (DD 1 ) comprises a CH3 domain containing mutations D399Q, D/E356Q, K370E, Y349K and S354K according to EU numbering, and said second dimerization domain the domain (DD 2 ) comprises a CH3 domain containing mutations D399Q, E357Q, K439E, Y349D and S354D according to EU numbering;
b. said first dimerization domain (DD 1 ) comprises a CH3 domain containing mutations D399N, D/E356Q, K370E and L351W according to EU numbering, and said second dimerization domain ( DD 2 ) contains a CH3 domain containing mutations D399N, E357Q, K439E and L351R according to EU numbering;
c. said first dimerization domain (DD 1 ) comprises a CH3 domain containing mutations D399N, D/E356Q, K370E and S354M according to EU numbering, and said second dimerization domain ( DD 2 ) contains a CH3 domain containing mutations D399N, E357Q, K439E and L351Y according to EU numbering;
d. said first dimerization domain (DD 1 ) comprises a CH3 domain containing mutations D399N, D/E356Q, K370E and T350I according to EU numbering, and said second dimerization domain ( DD 2 ) contains a CH3 domain containing mutations D399N, E357Q, K439E and T350I according to EU numbering;
e. said first dimerization domain (DD 1 ) comprises a CH3 domain containing mutations D399N, D/E356Q, K370E and T350V according to EU numbering, and said second dimerization domain ( DD 2 ) contains a CH3 domain containing mutations D399N, E357Q, K439E and T350V according to EU numbering,
f. said first dimerization domain (DD 1 ) comprises a CH3 domain containing mutations D399N, D/E356Q, K370E and P352R according to EU numbering, and said second dimerization domain ( DD 2 ) contains a CH3 domain containing mutations D399N, E357Q, K439E and L351R according to EU numbering, or
g. said first dimerization domain (DD 1 ) comprises a CH3 domain containing mutations D399N, D/E356Q, K370E and P352E according to EU numbering, and said second dimerization domain ( DD 2 ) contains a CH3 domain containing mutations D399N, E357Q, K439E and L351R according to EU numbering ;
protein complex.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962951701P | 2019-12-20 | 2019-12-20 | |
US62/951,701 | 2019-12-20 | ||
PCT/CA2020/051753 WO2021119832A1 (en) | 2019-12-20 | 2020-12-18 | Polypeptides, protein complexes and method for making same |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2023507033A JP2023507033A (en) | 2023-02-20 |
JPWO2021119832A5 true JPWO2021119832A5 (en) | 2023-12-27 |
Family
ID=76476896
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022538373A Pending JP2023507033A (en) | 2019-12-20 | 2020-12-18 | Polypeptides, protein complexes and methods of making them |
Country Status (8)
Country | Link |
---|---|
US (1) | US20230242676A1 (en) |
EP (1) | EP4077374A4 (en) |
JP (1) | JP2023507033A (en) |
CN (1) | CN115003693A (en) |
AR (1) | AR120870A1 (en) |
CA (1) | CA3171363A1 (en) |
TW (1) | TW202136294A (en) |
WO (1) | WO2021119832A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3231417A1 (en) * | 2021-09-10 | 2023-03-16 | Jian Shi | Anti-ang2 antibody, preparation method therefor, and application thereof |
WO2024073842A1 (en) * | 2022-10-03 | 2024-04-11 | Kisoji Biotechnology Inc. | Multispecific binding agents targeting dopamine receptor d2 and methods of use thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9738707B2 (en) * | 2011-07-15 | 2017-08-22 | Biogen Ma Inc. | Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto |
LT2794905T (en) * | 2011-12-20 | 2020-07-10 | Medimmune, Llc | Modified polypeptides for bispecific antibody scaffolds |
KR20180020142A (en) * | 2015-05-01 | 2018-02-27 | 인히브릭스 엘피 | Type III scaffold targeting molecules |
WO2016192613A1 (en) * | 2015-06-01 | 2016-12-08 | 中山大学 | Bivalent antibody having single-domain antigen-binding fragment fused to conventional fab fragment |
JP7328761B2 (en) * | 2016-01-11 | 2023-08-17 | インヒブルクス インコーポレイテッド | Multivalent multispecific OX40 binding fusion proteins |
-
2020
- 2020-12-18 CN CN202080094676.5A patent/CN115003693A/en active Pending
- 2020-12-18 US US17/786,708 patent/US20230242676A1/en active Pending
- 2020-12-18 WO PCT/CA2020/051753 patent/WO2021119832A1/en unknown
- 2020-12-18 JP JP2022538373A patent/JP2023507033A/en active Pending
- 2020-12-18 EP EP20902077.5A patent/EP4077374A4/en active Pending
- 2020-12-18 CA CA3171363A patent/CA3171363A1/en active Pending
- 2020-12-21 AR ARP200103608A patent/AR120870A1/en unknown
- 2020-12-21 TW TW109145364A patent/TW202136294A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2020510422A5 (en) | ||
JP2021098732A5 (en) | ||
CN111454357B (en) | Development and application of tumor therapeutic agent containing antibody | |
JP2019525738A5 (en) | ||
JP2021035388A5 (en) | Multispecific binding protein targeting CAIX, ANO1, mesoterin, TROP2 or claudin-18.2. | |
IL299221A (en) | Cd3 binding antibodies | |
JPWO2019129221A5 (en) | ||
JP2021503455A5 (en) | ||
RU2021110369A (en) | PROTEINS BINDING NKG2D, CD16 AND TUMOR ASSOCIATED ANTIGEN | |
JP2020533311A5 (en) | Proteins that bind to NKG2D, CD16 and Nectin4 | |
JP2021098733A5 (en) | ||
JP2022009816A5 (en) | ||
JP2023106433A5 (en) | ||
RU2019134462A (en) | ANTIBODIES BINDING WITH STEAP-1 | |
JPWO2020076970A5 (en) | ||
FI3765525T3 (en) | Anti-her2 biparatopic antibody-drug conjugates and methods of use | |
JPWO2021119832A5 (en) | ||
JPWO2020011968A5 (en) | ||
JPWO2020011964A5 (en) | ||
JPWO2019137541A5 (en) | ||
JPWO2020011970A5 (en) | ||
JPWO2020011966A5 (en) | ||
JP2020502233A5 (en) | ||
JPWO2020033587A5 (en) | ||
JPWO2021030680A5 (en) |